In the discovery stage, companies face a critical challenge: balancing innovation speed with regulatory readiness.

AI models used in target identification and lead optimization often lack proper validation documentation.

Preclinical data may not meet GxP standards, creating downstream compliance gaps that delay clinical development.

Patient-derived data requires secure governance from the start, but traditional approaches add complexity and slow innovation.